FDA approves first treatment for acid sphingomyelinase deficiency
Opinion: Cutting COVID isolation and mask mandates will mean more damage to business and health in the long run
5 September 2022The neonatal ketone body is important for primordial follicle pool formation and regulates ovarian aging in mice
5 September 2022FDA approves first treatment for acid sphingomyelinase deficiency
The U.S. Food and Drug Administration has approved Xenpozyme (olipudase alfa) for pediatric and adult patients with acid sphingomyelinase deficiency (ASMD), a rare genetic disease.
